西安国际医学中心医院神经外科;
目的 探讨血清miR-15a、miR-24水平对功能性垂体腺瘤患者术后复发的预测效能。方法 选取2017年6月至2022年6月于西安国际医学中心医院手术治疗的107例功能性垂体腺瘤患者作为研究对象，术后随访2年，根据是否复发将患者分为复发组（n=22）和未复发组（n=85）。收集研究对象临床资料，并在术后5 d采用实时荧光定量PCR方法检测患者血清miR-15a、miR-24水平。采用受试者工作特性（ROC）曲线分析血清miR-15a、miR-24对功能性垂体腺瘤患者术后复发的预测价值；采用多因素Logistic回归分析功能性垂体腺瘤患者术后复发的影响因素。结果 复发组患者血清miR-15a、miR-24水平均明显低于未复发组患者（P<0.05）。血清miR-15a、miR-24预测功能性垂体腺瘤患者术后复发的曲线下面积（AUC）分别为0.781(95%CI:0.736～0.831)、0.819(95%CI:0.774～0.869)，两者联合预测的AUC为0.906(95%CI:0.856～0.951)。单因素分析结果显示：复发组患者肿瘤分期Ⅲ～Ⅳ期比例、病理类型侵袭比例明显高于未复发组（P<0.05）。多因素回归分析显示：肿瘤分期Ⅲ～Ⅳ期（OR=2.307,95%CI:1.433～3.715）、病理类型侵袭（OR=2.140,95%CI:1.266～3.619）、miR-15a≤0.52(OR=2.795,95%CI:1.820～4.294)、miR-24≤0.91(OR=2.649,95%CI:1.704～4.116)是功能性垂体腺瘤患者术后复发的危险因素（P<0.05）。结论 血清mi R-15a、mi R-24降低与功能性垂体腺瘤患者术后复发密切相关，二者对功能性垂体腺瘤患者术后复发具有一定的预测价值，且两者联合检测预测效能更佳。
| 154 | 0 | 23 |
| 下载次数 | 被引频次 | 阅读次数 |
1 DAIL AF, BECKERS A. The epidemiology of pituitary adenomas[J].Endocrinol Metab Clin North Am, 2020, 49(3):347-355.
2 MELMED S. Pituitary-tumor endocrinopathies[J]. N Engl J Med, 2020,382(10):937-950.
3 INOMOTO C, TSHARA S, OYAMA K, et al. Molecular, functional,and histopathological classification of the pituitary neuroendocrine neoplasms[J]. Brain Tumor Pathol, 2021, 38(3):183-188.
4 鲁彦,刘景云,张人枭.神经内镜辅助下经鼻蝶窦入路手术对垂体瘤PRL、HGH及ACTh水平的影响[J].分子诊断与治疗杂志, 2022,14(10):1684-1687.
5 章薇.内窥镜经鼻-蝶窦手术切除垂体腺瘤:缩短住院时间、提高术后恢复的首选方案[J].中华神经外科疾病研究杂志, 2024, 18(3):85.
6 HO PTB, CLARK IM, LE LTT. MicroRNA-based diagnosis and therapy[J]. Int J Mol Sci, 2022, 23(13):7167.
7 HU JJ, QIN LJ, LIU ZY, et al. miR-15a regulates oxygen glucose deprivation/reperfusion(OGD/R)-induced neuronal injury by targeting BDNF[J]. Kaohsiung J Med Sci, 2020, 36(1):27-34.
8 赵倩,耿德勤,程言博,等.入院时血清miR-20b、miR-24、miR-137水平对老年急性缺血性脑卒中患者预后的预测价值[J].中国临床保健杂志, 2024, 27(3):326-329.
9 KLEINSCHMIDT-DEMASTERS BK. Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma:Immunohistochemical insights[J]. J Neuropathol Exp Neurol, 2024, 83(9):708-721.
10 中国垂体腺瘤协作组,中华医学会神经外科学分会.中国复发性垂体腺瘤诊治专家共识(2019)[J].中华医学杂志, 2019, 99(19):1449-1453.
11 SANEI TAHERI M, KIMIA F, MEHRNAHAD M, et al. Accuracy of diffusion-weighted imaging-magnetic resonance in differentiating functional from non-functional pituitary macro-adenoma and classification of tumor consistency[J]. Neuroradiol J, 2019, 32(2):74-85.
12 苏晓怡,孟磊,马文思.护理服务模块式输出法在垂体瘤假包膜囊外切除术患者中的应用研究[J].保健医学研究与实践, 2022, 19(6):77-80.
13 COTE DJ, SMITH TR, KAISER UB, et al. Body habitus across the lifespan and risk of pituitary adenoma[J]. J Clin Endocrinol Metab,2021, 106(4):e1591-e1602.
14 CAPATINA C, HANZU FA, HINOJOSA-AMAYA JM, et al. Medical treatment of functional pituitary adenomas, trials and tribulations[J]. J Neurooncol, 2024, 168(2):197-213.
15 GONZALEZ-VIRLA B, VARGAS-ORTEGA G, ROMERO-GAMEROS CA. Radiotherapy and mortality in pituitary adenomas[J]. Arch Med Res, 2023, 54(8):102900.
16 DE VRIES F, LOBATTO DJ, VERSTEGEN MJT, et al. Outcome squares integrating efficacy and safety, as applied to functioning pituitary adenoma surgery[J]. J Clin Endocrinol Metab, 2021, 106(9):e3300-e3311.
17 HAYHURST C, TAYLOR PN, LANSDOWN AJ, et al. Current perspectives on recurrent pituitary adenoma:The role and timing of surgery vs adjuvant treatment[J]. Clin Endocrinol(Oxf), 2020, 92(2):89-97.
18 SPADA A, MANTOVANI G, LANIA AG, et al. Pituitary tumors:genetic and molecular factors underlying pathogenesis and clinical behavior[J]. Neuroendocrinology, 2022, 112(1):15-33.
19 徐笑,魏栋,王协锋,等.血清GH和AGR2水平预测功能性垂体腺瘤患者术后复发的临床价值[J].热带医学杂志, 2024, 24(8):1145-1149.
20 HUSSEN BM, HIDAYAT HJ, SALIHI A, et al. MicroRNA:A signature for cancer progression[J]. Biomed Pharmacother, 2021, 138(1):111528.
21 RAMPROSAND S, GOVINDEN-SOULANGE J, RANGHOO-SANMUKHIYA VM, et al. miRNA, phytometa-bolites and disease:Connecting the dots[J]. Phytother Res, 2024, 38(9):4570-4591.
22 HILL M, TRAN N. miRNA interplay:mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4):dmm047662.
23 FERRAGUT CARDOSO AP, BANERJEE M, NAIL AN, et al. miRNA dysregulation is an emerging modulator of genomic instability[J]. Semin Cancer Biol, 2021, 76(1):120-131.
24 郭潮,刘玉琼,张慧,等.急性心肌梗死病人血清miR-30a、miR-24、miR-155水平的变化及临床意义[J].中西医结合心脑血管病杂志,2023, 21(2):345-348.
25 WU W, CAO L, JIA Y, et al. Emerging roles of miRNA, lncRNA, circRNA,and their cross-talk in pituitary adenoma[J]. Cells, 2022, 11(18):2920.
26 CHANG M, JIANG S, GUO X, et al. Exosomal RNAs in the development and treatment of pituitary adenomas[J]. Front Endocrinol(Lausanne), 2023, 14(1):1142494.
27 RAHMANI F, MOHAMMED AL-ASADY A, HANAIE R, et al. Interplay between lncRNA/miRNA and Wnt/?-catenin signaling in brain cancer tumorigenesis[J]. Excli J, 2023, 22(1):1211-1222.
28 LI L, YU S, CHEN J, et al. miR-15a and miR-20b sensitize hepatocellular carcinoma cells to sorafenib through repressing CDC37L1 and consequent PPIA downregulation[J]. Cell Death Discov, 2022, 8(1):297.
29 DENG X, LIANG C, QIAN L, et al. miR-24 targets HMOX1 to regulate inflammation and neurofunction in rats with cerebral vasospasm after subarachnoid hemorrhage[J]. Am J Transl Res, 2021, 13(3):1064-1074.
30 JIANG Q, ZHANG Z, SUN Y, et al. miR-24 protects against ischemia-induced brain damage in rats via regulating microglia polarization by targeting Clcn3[J]. Neurosci Lett, 2021, 759(1):135998.
31 MUKHERJEE S, SHELAR B, KRISHNA S. Versatile role of miR-24 /24-1*/24-2*expression in cancer and other human diseases[J]. Am J Transl Res, 2022, 14(1):20-54.
基本信息:
DOI：
中图分类号:R736.4
引用信息:
[1]郑涛,车沅沅,褚冬等.血清miR-15a、miR-24水平对功能性垂体腺瘤患者术后复发的预测效能[J].中华神经外科疾病研究杂志,2025,19(02):17-21.
基金信息:
国家自然科学基金面上项目（81572470）